Compare Stocks → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:AUPHNASDAQ:MDGLNYSE:MYOVNASDAQ:ZGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.40-6.0%$1.57$0.78▼$2.48$293.12M0.944.15 million shs4.04 million shsAUPHAurinia Pharmaceuticals$5.12-0.8%$5.18$4.71▼$12.43$732.26M1.362.10 million shs1.01 million shsMDGLMadrigal Pharmaceuticals$217.96-7.5%$241.05$119.76▼$313.11$4.64B-0.33525,087 shs779,851 shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+8.76%+12.88%0.00%-11.31%+36.70%AUPHAurinia Pharmaceuticals+1.18%+2.99%+2.18%-34.93%-55.36%MDGLMadrigal Pharmaceuticals+2.49%+17.16%-3.07%+16.94%-23.11%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.669 of 5 stars3.52.00.04.01.80.80.6AUPHAurinia Pharmaceuticals1.7267 of 5 stars3.43.00.00.02.50.00.6MDGLMadrigal Pharmaceuticals4.6073 of 5 stars4.41.00.04.61.94.20.6MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00257.14% UpsideAUPHAurinia Pharmaceuticals2.75Moderate Buy$10.0095.31% UpsideMDGLMadrigal Pharmaceuticals2.73Moderate Buy$356.7363.67% UpsideMYOVMyovant SciencesN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/ACurrent Analyst RatingsLatest ZGNX, MDGL, AKBA, MYOV, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024MDGLMadrigal PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$150.003/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/20/2024MDGLMadrigal PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$325.00 ➝ $405.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/15/2024MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$405.00 ➝ $425.003/15/2024MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$338.00 ➝ $377.003/15/2024MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$320.00 ➝ $375.003/15/2024MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$351.00 ➝ $397.003/15/2024MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$382.00 ➝ $389.003/15/2024MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$349.00 ➝ $390.003/15/2024MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$337.00 ➝ $410.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.51N/AN/A($0.16) per share-8.75AUPHAurinia Pharmaceuticals$175.51M4.17N/AN/A$2.63 per share1.95MDGLMadrigal PharmaceuticalsN/AN/AN/AN/A$20.53 per shareN/AMYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/9/2024 (Confirmed)AUPHAurinia Pharmaceuticals-$78.02M-$0.43N/A9.14N/A-32.69%-15.06%-10.57%8/1/2024 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$19.94N/AN/AN/AN/A-219.39%-98.75%5/7/2024 (Confirmed)MYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/AZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest ZGNX, MDGL, AKBA, MYOV, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AAKBAAkebia Therapeutics-$0.09N/A+$0.09N/AN/AN/A 5/7/2024N/AMDGLMadrigal Pharmaceuticals-$6.06-$7.38-$1.32N/AN/AN/A 3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million2/28/2024Q4 2023MDGLMadrigal Pharmaceuticals-$5.26-$5.68-$0.42-$5.68N/AN/A2/15/202412/31/2023AUPHAurinia Pharmaceuticals-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03AUPHAurinia Pharmaceuticals0.195.605.05MDGLMadrigal Pharmaceuticals0.285.385.38MYOVMyovant SciencesN/A1.571.45ZGNXZogenix0.883.634.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AUPHAurinia Pharmaceuticals36.83%MDGLMadrigal Pharmaceuticals98.50%MYOVMyovant Sciences30.62%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%AUPHAurinia Pharmaceuticals4.30%MDGLMadrigal Pharmaceuticals23.92%MYOVMyovant Sciences1.90%ZGNXZogenix4.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.37 million201.33 millionOptionableAUPHAurinia Pharmaceuticals300143.02 million136.87 millionOptionableMDGLMadrigal Pharmaceuticals37621.28 million16.19 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableZGNXZogenix21856.23 million53.92 millionOptionableZGNX, MDGL, AKBA, MYOV, and AUPH HeadlinesSourceHeadlineHwasung Industrial Co Ltd 002460morningstar.com - March 23 at 1:30 AMOrally Inhaled Dihydroergotaminemedscape.com - February 13 at 4:11 PMMRI in Headachemedscape.com - August 25 at 10:47 PMKratom: What We Knowmedscape.com - August 13 at 5:03 PMAlcon (NYSE: ALC)fool.com - July 6 at 8:34 PMLongeveron Inc Ordinary Shares - Class Amorningstar.com - May 21 at 12:24 AMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journalnews.google.com - May 10 at 11:58 PMGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRnews.google.com - May 4 at 4:03 PMNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan Newsnews.google.com - April 28 at 12:42 PMThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headachemedscape.com - April 25 at 2:50 PMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan Newsnews.google.com - April 24 at 9:21 AMAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journalnews.google.com - April 24 at 9:21 AMDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journalnews.google.com - April 20 at 12:29 AMForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comnews.google.com - April 19 at 7:28 PMDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome Newsnews.google.com - April 18 at 3:52 PMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journalnews.google.com - April 17 at 7:30 PMSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journalnews.google.com - April 17 at 7:30 PMEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journalnews.google.com - April 17 at 9:27 AMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswirenews.google.com - April 17 at 9:27 AMLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRnews.google.com - April 14 at 8:40 AMNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journalnews.google.com - April 13 at 5:40 PMNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRnews.google.com - April 12 at 1:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Aurinia PharmaceuticalsNASDAQ:AUPHAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Madrigal PharmaceuticalsNASDAQ:MDGLMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Myovant SciencesNYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.ZogenixNASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.